TY - JOUR
T1 - The effect of tamoxifen on the lipid profile in women
T2 - A systematic review and meta-analysis of randomized controlled trials
AU - Alomar, Sara Abdulrahman
AU - Găman, Mihnea Alexandru
AU - Prabahar, Kousalya
AU - Arafah, Omar Ahnaf
AU - Almarshood, Ftoon
AU - Baradwan, Saeed
AU - Aboudi, Saud Abdullah Saud
AU - Abuzaid, Mohammed
AU - Almubarki, Abdullah A.M.A.
AU - Alomar, Osama
AU - Al-Badawi, Ismail A.
AU - Salem, Hany
AU - Abu-Zaid, Ahmed
N1 - Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2022/3
Y1 - 2022/3
N2 - Background and aim: The effect of tamoxifen administration on serum lipids in females remains unclear. The studies which have explored this topic have produced conflicting results, probably due to discrepancies in the length of the intervention, differences in baseline variables or other factors. To answer this research question, we decided to conduct this systematic review and meta-analysis to assess the effects of tamoxifen on the lipid profile in women. Methods: A comprehensive search was conducted in Web of Science, Scopus, PubMed/Medline and Embase, from the inception of these databases up to June 2021. We used a random effects meta-analysis to generate the combined results. Results: The overall findings were generated from 18 eligible trials. As compared to placebo, tamoxifen led to a notable reduction of the total cholesterol (TC) (WMD: −23.03 mg/dL, 95% CI: −25.94 to −20.12, P˂0.001), and the low-density lipoprotein-cholesterol (LDL-C) (WMD: −18.68 mg/dL, 95% CI: −24.31 to −13.04, P˂0.001). However, tamoxifen did not alter triglycerides (TG) concentrations (WMD: +1.06 mg/dL, 95% CI: −11.08 to 13.20, P = 0.864) significantly. A pronounced reduction of the high-density lipoprotein-cholesterol (HDL–C) was noted in the RCTs with a duration of ≤52 weeks (WMD: −2.06 mg/dL) and when tamoxifen was administered in participants with a BMI ≥25 kg/m2 (WMD: −1.42 mg/dL). Notable reductions in TC (WMD: −23.57 mg/dL) and LDL-C (WMD: −19.21 mg/dL) was detected when the dose of tamoxifen was ≥20 mg/day. Moreover, a significant reduction of TC (WMD: −20.23 mg/dL) and LDL-C (WMD: −24.13 mg/dL) was observed in the RCTs with a duration of ≤52 weeks. Conclusion: Tamoxifen can alter the lipid profile in females, particularly by decreasing TC, LDL-C and HDL–C. Tamoxifen can further reduce TC and LDL-C if the dose of administration is ≥20 mg/day, the treatment duration is ≤52 weeks and if it prescribed in subjects with dyslipidemia.
AB - Background and aim: The effect of tamoxifen administration on serum lipids in females remains unclear. The studies which have explored this topic have produced conflicting results, probably due to discrepancies in the length of the intervention, differences in baseline variables or other factors. To answer this research question, we decided to conduct this systematic review and meta-analysis to assess the effects of tamoxifen on the lipid profile in women. Methods: A comprehensive search was conducted in Web of Science, Scopus, PubMed/Medline and Embase, from the inception of these databases up to June 2021. We used a random effects meta-analysis to generate the combined results. Results: The overall findings were generated from 18 eligible trials. As compared to placebo, tamoxifen led to a notable reduction of the total cholesterol (TC) (WMD: −23.03 mg/dL, 95% CI: −25.94 to −20.12, P˂0.001), and the low-density lipoprotein-cholesterol (LDL-C) (WMD: −18.68 mg/dL, 95% CI: −24.31 to −13.04, P˂0.001). However, tamoxifen did not alter triglycerides (TG) concentrations (WMD: +1.06 mg/dL, 95% CI: −11.08 to 13.20, P = 0.864) significantly. A pronounced reduction of the high-density lipoprotein-cholesterol (HDL–C) was noted in the RCTs with a duration of ≤52 weeks (WMD: −2.06 mg/dL) and when tamoxifen was administered in participants with a BMI ≥25 kg/m2 (WMD: −1.42 mg/dL). Notable reductions in TC (WMD: −23.57 mg/dL) and LDL-C (WMD: −19.21 mg/dL) was detected when the dose of tamoxifen was ≥20 mg/day. Moreover, a significant reduction of TC (WMD: −20.23 mg/dL) and LDL-C (WMD: −24.13 mg/dL) was observed in the RCTs with a duration of ≤52 weeks. Conclusion: Tamoxifen can alter the lipid profile in females, particularly by decreasing TC, LDL-C and HDL–C. Tamoxifen can further reduce TC and LDL-C if the dose of administration is ≥20 mg/day, the treatment duration is ≤52 weeks and if it prescribed in subjects with dyslipidemia.
KW - HDL-C
KW - LDL-C
KW - Lipid profile
KW - Tamoxifen
KW - Total cholesterol
KW - Triglycerides
UR - http://www.scopus.com/inward/record.url?scp=85122158865&partnerID=8YFLogxK
U2 - 10.1016/j.exger.2021.111680
DO - 10.1016/j.exger.2021.111680
M3 - Review article
C2 - 34973347
AN - SCOPUS:85122158865
SN - 0531-5565
VL - 159
JO - Experimental Gerontology
JF - Experimental Gerontology
M1 - 111680
ER -
